Metabolex-36 is used as an FFA4 agonist to study FFA4 function, particularly in pancreatic δ-cells; it is employed to investigate the role of FFA4 in ghrelin secretion and somatostatin release; it inhibits basal ghrelin secretion from primary gastric mucosal cells and reduces plasma ghrelin levels in fasted mice upon oral administration; it also suppresses somatostatin release from primary gastric epithelial cells, with no effect observed in FFA4 knockout (FFA4KO) mice.